News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe

News

Webcast

Webcasts

March 27, 2024

Navigating Healthcare with Patients at the Center

Author(s):

Oracle

Webinar Date/Time: Thursday, April 18, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

Clinical trial protocols often focus on the clinical objectives of the trial, without considering the implications of the design on the patients participating in the trial – this can contribute to lower trial participation, increased drop-out rates, and reduced operational efficiency. Could incorporating the patient voice in clinical trial design and execution address these issues and provide key insight for innovations in healthcare?

Register Free:
https://www.pharmexec.com/pe/navigating-healthcare

Event Overview:

In the realm of healthcare, patients are now more involved in their own care, with easy access to information through the internet and the use of new technologies that empower them to generate and share data. Patients are not only the beneficiaries of scientific knowledge but are creators of scientific knowledge. As a result, (bio)pharma companies are recognizing the potential benefits of engaging with highly motivated patients and patient organizations. This approach not only reduces costs but also enhances the success of clinical trials.

Join this webinar to learn more about including patients as partners in clinical research and utilizing technology to collect relevant patient-centric, real-world data to improve the design and outcomes of clinical trial research studies, advocate for patient equity, and advance scientific and drug discovery.

Key Learning Objectives

  • Understand the impact of trial design on participants and why a patient-centric approach can lead to more successful clinical trials.
  • Become familiar with FAIR and CARE principles and learn how to ensure proper data standards across many data constituents, collaborations, and frameworks.
  • Understand how diverse and inclusive patient recruitment could serve as key access enablers for patients to receive clinical research as a care option.
  • Learn how to implement patient assessments in remote settings and ensure results are robust and meaningful.
  • Hear perspective on what to expect from future trial models based on current trends in the industry.


Who Should Attend

  • Clinical researchers, academic researchers, data scientists, patient engagement leads, and clinical decision teams responsible for:
    • Research data computing and planning
    • Clinical development planning and study design
    • Management of patients and measurement of clinical outcomes
    • Clinical data management, collecting and evaluating trial metrics.
    • Project management of studies, process optimization, and operational excellence


  • Sponsors and those with CRO roles who are responsible for:
    • Clinical development planning
    • Study design
    • Country and site identification, feasibility assessment, selection, and activation
    • Clinical data management, collecting and evaluating trial metrics
    • Project management of studies, process optimization, and operational excellence


Full Agenda
Thursday, March 21st: 
10:00 am EDT Addressing Diversity in Patient Recruitment for Clinical Research
Katherine Vandebelt, Global Vice President, Clinical Innovation; Oracle, and other non-Oracle speakers.


11:00 am EDT Addressing Enrollment and Trial Inefficiencies With Patients as Partners
Rebecca Nash, Principal, Real-World Evidence; Oracle 
Kathy Beusterien, Senior Research Scientist; Oracle, and other non-Oracle speakers.


12:00 pm EDT Do Decentralized Trials Still Offer Clinical Precision in Challenging Patient Populations?
Gillian Worman, Director, Product Strategy; Oracle
David Blackman, Executive Director, Digital Trials Strategy; Oracle, and other non-Oracle speakers.


1:00 pm EDT Advancing Drug Discovery and Treatment Options with Patients and Citizen Science
Amy Sorrells, Senior Director; Oracle, and other non-Oracle speakers.

2:00 pm EDT Accelerating Precision Oncology with Artificial Intelligence
Elise Berliner, Global Senior Principal of Real-World Evidence Strategy; Oracle, and other non-Oracle speakers.

Speakers:

Katherine Vandebelt
Global Vice President, Clinical Innovation
Oracle

Rebecca Nash
Principal, Real-World Evidence
Oracle

Kathy Beusterien
Senior Research Scientist
Oracle

Gillian Worman
Director, Product Strategy
Oracle

David Blackman
Executive Director, Digital Trials Strategy
Oracle

Amy Sorrells
Senior Director
Oracle

Elise Berliner
Global Senior Principal of Real-World Evidence Strategy
Oracle

Register Free:
https://www.pharmexec.com/pe/navigating-healthcare

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Related Content
Advertisement
Ahmet Tutuncu
August 19th 2025

Creating Momentum for COPD Treatments: Q&A with Dr. Ahment Tutuncu

Mike Hollan
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 19th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
Stock.adobe.com
August 19th 2025

Pfizer’s Sickle Cell Treatment Fails Phase 3 Study

Nicholas Jacobus
Peter Ax, UpScriptHealth
August 19th 2025

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
Sarepta, Arrowhead Advance RNAi Programs with $100 Million Milestone Payment, Stock Sale
August 19th 2025

Sarepta, Arrowhead Advance RNAi Programs with $100 Million Milestone Payment, Stock Sale

Don Tracy, Associate Editor
Novartis’ Novel Human Monoclonal Antibody Achieves Primary Endpoints in Pair of Phase III Trials for Sjögren’s Disease
August 19th 2025

Novartis’ Novel Human Monoclonal Antibody Achieves Primary Endpoints in Pair of Phase III Trials for Sjögren’s Disease

Don Tracy, Associate Editor
Related Content
Advertisement
Ahmet Tutuncu
August 19th 2025

Creating Momentum for COPD Treatments: Q&A with Dr. Ahment Tutuncu

Mike Hollan
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 19th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
Stock.adobe.com
August 19th 2025

Pfizer’s Sickle Cell Treatment Fails Phase 3 Study

Nicholas Jacobus
Peter Ax, UpScriptHealth
August 19th 2025

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
Sarepta, Arrowhead Advance RNAi Programs with $100 Million Milestone Payment, Stock Sale
August 19th 2025

Sarepta, Arrowhead Advance RNAi Programs with $100 Million Milestone Payment, Stock Sale

Don Tracy, Associate Editor
Novartis’ Novel Human Monoclonal Antibody Achieves Primary Endpoints in Pair of Phase III Trials for Sjögren’s Disease
August 19th 2025

Novartis’ Novel Human Monoclonal Antibody Achieves Primary Endpoints in Pair of Phase III Trials for Sjögren’s Disease

Don Tracy, Associate Editor
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.